Adhera Therapeutics, Inc.
ATRX
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 269.50K | 296.00K | 353.00K | 361.00K | 547.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 269.50K | 296.00K | 353.00K | 361.00K | 547.60K |
| Operating Income | -269.50K | -296.00K | -353.00K | -361.00K | -547.60K |
| Income Before Tax | -3.54M | 271.00K | -886.00K | -335.00K | -1.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.54M | 271.00K | -886.00K | -335.00K | -1.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.54M | 271.00K | -886.00K | -335.00K | -1.80M |
| EBIT | -269.50K | -296.00K | -353.00K | -361.00K | -547.60K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.83 | 0.07 | -0.29 | -0.12 | -0.57 |
| Normalized Basic EPS | -0.52 | 0.04 | -0.18 | -0.07 | -0.37 |
| EPS Diluted | -0.83 | -0.01 | -0.29 | -0.12 | -0.57 |
| Normalized Diluted EPS | -0.52 | 0.00 | -0.18 | -0.07 | -0.37 |
| Average Basic Shares Outstanding | 4.30M | 3.46M | 3.18M | 3.17M | 3.16M |
| Average Diluted Shares Outstanding | 4.30M | 98.54M | 3.18M | 3.17M | 3.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
